Bioventus and LifeLink Tissue Bank entered an agreement to co-develop next-gen bone allograft for spine and trauma applications.
The partnership supports Bioventus’ strategy to grow sales of orthobiologic products—both existing and those to-be-developed.
For instance, earlier this month, the company announced an extension of its agreement with Seikagaku to exclusively distribute SUPARTZ FX™ in the U.S. through May 2028. Further, in January, Bioventus contributed $2.5MM in funding for CartiHeal’s ongoing clincial study of the Agili-C™ inorganic calcium carbonate scaffold implant for the treatment of joint surface lesions.
Bioventus and LifeLink Tissue Bank entered an agreement to co-develop next-gen bone allograft for spine and trauma applications.
The partnership supports Bioventus' strategy to grow sales of orthobiologic products—both existing and those to-be-developed.
For instance, earlier this month, the company announced an extension of its agreement with...
Bioventus and LifeLink Tissue Bank entered an agreement to co-develop next-gen bone allograft for spine and trauma applications.
The partnership supports Bioventus’ strategy to grow sales of orthobiologic products—both existing and those to-be-developed.
For instance, earlier this month, the company announced an extension of its agreement with Seikagaku to exclusively distribute SUPARTZ FX™ in the U.S. through May 2028. Further, in January, Bioventus contributed $2.5MM in funding for CartiHeal’s ongoing clincial study of the Agili-C™ inorganic calcium carbonate scaffold implant for the treatment of joint surface lesions.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
